248 related articles for article (PubMed ID: 30819233)
1. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A
Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566
[TBL] [Abstract][Full Text] [Related]
4. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
5. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
[TBL] [Abstract][Full Text] [Related]
6. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
[TBL] [Abstract][Full Text] [Related]
7. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Predictive Value of
Jeffreys SA; Becker TM; Khan S; Soon P; Neubauer H; de Souza P; Powter B
Front Endocrinol (Lausanne); 2022; 13():895729. PubMed ID: 35784572
[TBL] [Abstract][Full Text] [Related]
9. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
Mrhalová M; Kodet R; Strnad P
Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
[TBL] [Abstract][Full Text] [Related]
10. Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.
Dedes KJ; Lopez-Garcia MA; Geyer FC; Lambros MB; Savage K; Vatcheva R; Wilkerson P; Wetterskog D; Lacroix-Triki M; Natrajan R; Reis-Filho JS
Breast Cancer Res Treat; 2010 Dec; 124(3):653-66. PubMed ID: 20213079
[TBL] [Abstract][Full Text] [Related]
11. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
12. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
Elsheikh S; Green AR; Aleskandarany MA; Grainge M; Paish CE; Lambros MB; Reis-Filho JS; Ellis IO
Breast Cancer Res Treat; 2008 May; 109(2):325-35. PubMed ID: 17653856
[TBL] [Abstract][Full Text] [Related]
13. CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.
Aleksakhina SN; Kramchaninov MM; Mikushina AD; Kubrina SE; Petkau VV; Ivantsov AO; Moiseyenko VM; Imyanitov EN; Iyevleva AG
Clin Transl Oncol; 2021 Apr; 23(4):874-881. PubMed ID: 32880048
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
Reis-Filho JS; Savage K; Lambros MB; James M; Steele D; Jones RL; Dowsett M
Mod Pathol; 2006 Jul; 19(7):999-1009. PubMed ID: 16648863
[TBL] [Abstract][Full Text] [Related]
15. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
[TBL] [Abstract][Full Text] [Related]
16. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
[TBL] [Abstract][Full Text] [Related]
17. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 gene amplification is highly homogeneous in breast cancer.
Burandt E; Grünert M; Lebeau A; Choschzick M; Quaas A; Jänicke F; Müller V; Scholz U; Bokemeyer C; Petersen C; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Wilczak W
Breast Cancer; 2016 Jan; 23(1):111-119. PubMed ID: 24862872
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays.
Bièche I; Olivi M; Noguès C; Vidaud M; Lidereau R
Br J Cancer; 2002 Feb; 86(4):580-6. PubMed ID: 11870541
[TBL] [Abstract][Full Text] [Related]
20. CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients.
Shimazaki A; Kubo M; Kurata K; Takao Y; Hayashi S; Harada Y; Kawaji H; Kaneshiro K; Yamada M; Kai M; Nakamura M
Anticancer Res; 2022 Aug; 42(8):4071-4077. PubMed ID: 35896251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
